Stuart Grant increased his position of Eyenovia, Inc (EYEN) by 35,000 share this month.
|
COMPANY INFORMATION
|
||
|
EYEN by TradingView
|
Company Info:
Eyenovia is a clinical stage ophthalmic company developing a pipeline of advanced therapeutics based on its proprietary microdose array print (MAP™) platform technology.
Eyenovia aims to achieve clinical microdosing of next-generation formulations of well-established ophthalmic pharmaceutical agents using its high-precision targeted ocular delivery system, which has the potential to replace conventional eyedropper delivery and improve safety, tolerability, patient compliance and topical delivery success for ophthalmic eye treatments.
Eyenovia aims to achieve clinical microdosing of next-generation formulations of well-established ophthalmic pharmaceutical agents using its high-precision targeted ocular delivery system, which has the potential to replace conventional eyedropper delivery and improve safety, tolerability, patient compliance and topical delivery success for ophthalmic eye treatments.
|
LATEST INSIDER ACTIVITY
|
||
|
INSIDER:
Stuart Grant
SHARES BOUGHT:
35,000
PURCHASE DATE:
03/05/2021 |
TITLE:
10% Ownership
% INCREASE:
1%
FILE DATE:
03/08/2021
|
|
|
INSIDER PURCHASE PRICE
$5.50
|
||
Insider Notes:
N/A
|
ANALYST RECOMMENDATION
|
||
|
TARGET PRICE:
$12 TARGET GAIN:
90% |
AVERAGE RATING:
BUY ANALYST COVERING:
4 |
|
| IMPORTANT DISCLOSURE | ||
|
TECHNICAL ANALYSIS
|
||
|
|
|
|